guest ::
| Home > Publications database > Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group > print |
| Home > Publications database > Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group > print |
| 001 | 909507 | ||
| 005 | 20230123110645.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noac131 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a 2128/33045 |2 Handle |
| 024 | 7 | _ | |a 35674736 |2 pmid |
| 024 | 7 | _ | |a WOS:000807656300001 |2 WOS |
| 037 | _ | _ | |a FZJ-2022-03213 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 0 |e Corresponding author |u fzj |
| 245 | _ | _ | |a Investigational PET tracers in neuro-oncology—What’s on the horizon? A report of the PET/RANO group |
| 260 | _ | _ | |a Oxford |c 2022 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1670836381_17320 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Many studies in patients with brain tumors evaluating innovative PET tracers have been published in recent years, and the initial results are promising. Here, the Response Assessment in Neuro-Oncology (RANO) PET working group provides an overview of the literature on novel investigational PET tracers for brain tumor patients. Furthermore, newer indications of more established PET tracers for the evaluation of glucose metabolism, amino acid transport, hypoxia, cell proliferation, and others are also discussed. Based on the preliminary findings, these novel investigational PET tracers should be further evaluated considering their promising potential. In particular, novel PET probes for imaging of translocator protein and somatostatin receptor overexpression as well as for immune system reactions appear to be of additional clinical value for tumor delineation and therapy monitoring. Progress in developing these radiotracers may contribute to improving brain tumor diagnostics and advancing clinical translational research. |
| 536 | _ | _ | |a 5252 - Brain Dysfunction and Plasticity (POF4-525) |0 G:(DE-HGF)POF4-5252 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 1 |u fzj |
| 700 | 1 | _ | |a Albert, Nathalie L |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Law, Ian |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Kim, Michelle M |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Villanueva-Meyer, Javier E |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Soffietti, Riccardo |0 0000-0002-9204-7038 |b 6 |
| 700 | 1 | _ | |a Wen, Patrick Y |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Weller, Michael |0 0000-0002-1748-174X |b 8 |
| 700 | 1 | _ | |a Tonn, Joerg C |0 P:(DE-HGF)0 |b 9 |
| 773 | _ | _ | |a 10.1093/neuonc/noac131 |g p. noac131 |0 PERI:(DE-600)2094060-9 |n 11 |p 1815–1826 |t Neuro-Oncology |v 24 |y 2022 |x 1522-8517 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/909507/files/Invoice_E15324838.pdf |
| 856 | 4 | _ | |y Published on 2022-06-08. Available in OpenAccess from 2023-06-08. |u https://juser.fz-juelich.de/record/909507/files/POSTPRINT.pdf |
| 909 | C | O | |o oai:juser.fz-juelich.de:909507 |p openaire |p open_access |p OpenAPC |p driver |p VDB |p openCost |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)143792 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)131777 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5252 |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Embargoed OpenAccess |0 StatID:(DE-HGF)0530 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-08 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-08 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2021 |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-08 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEURO-ONCOLOGY : 2021 |d 2022-11-08 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a APC |
| 980 | 1 | _ | |a APC |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|